YMAB(Delisted)
Y-mAbs Therapeutics·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 1
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About YMAB
Y-Mabs Therapeutics, Inc.
A company that develops novel antibody-based therapeutic products for the treatment of cancer
202 Carnegie Center, Suite 301, Princeton, NJ 08540
--
Y-mAbs Therapeutics, Inc., was incorporated under the laws of the State of Delaware on April 30, 2015. The Company is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer. The company is leveraging proprietary radioimmunotherapy and antibody platforms and expertise to develop a broad portfolio of innovative drugs.
Earnings Call
Q1/2025
Estimate EPS-0.2
Actual EPS-0.12
Estimate Revenue19.61M
Actual Revenue20.90M
Y-mAbs Therapeutics Q1 2025: Unpacking Contradictory Insights on Revenue, Studies, and Medicaid Dynamics
May 20,2025 01:04
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
YMAB has released its 2025 Q2 earnings. EPS was reported at -0.07, versus the expected -0.25, beating expectations. The chart below visualizes how YMAB has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
YMAB has released its 2025 Q2 earnings report, with revenue of 19.52M, reflecting a YoY change of -14.36%, and net profit of -3.24M, showing a YoY change of 64.98%. The Sankey diagram below clearly presents YMAB's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
